spacer
home > ict > spring 2020 > while the world waits
PUBLICATIONS
International Clinical Trials

While the World Waits




Although we don’t yet know if COVID-19 will be a seasonal disease, it may recycle with other respiratory pathogens in the winter respiratory season. With that said, Phase I and II studies can be executed at any time, although off season is typically preferred so as not to confound the data with natural disease acquisition. Phase III randomised, controlled efficacy studies of vaccines aimed at preventing lab-confirmed respiratory diseases are typically conducted with the season in mind and make for an intense time for sponsors, CROs, and sites. Regardless of the phase, a potential vaccine for a pandemic respiratory virus must contend with:

An Aggressive Calendar

With a pandemic such as COVID-19, time is of the essence as the virus claims lives, overwhelms the healthcare system, upends daily life, and destabilises the global economy. These studies must be made a priority, starting with ensuring sites are ready to go when the vaccine is available. There is generally no ‘wiggle room’ in the schedule.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
About the author

Cindy Dukes has over 40 years of diversified clinical experience, including 34 years of clinical research focused in infectious diseases, vaccines, oncology, women’s health, and rare diseases. At ICON, she is the therapeutic expert for vaccines and leads ICON’s Vaccine Centre of Excellence. She also provides strategic management and oversight for studies across a number of therapeutic areas, including pivotal Phase III trials that have supported the approval of 14 vaccines as well as numerous drugs in other therapeutic areas.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000

Cambridge and Wetherby, UK, 29 November 2021: Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AVA6000. This will allow the Group to expand its Phase 1 clinical trial, ALS-6000-101, into clinical trial sites in the United States.
More info >>

White Papers

Changing Structural Landscape for Comparator Drug Supply

ADAllen Pharma

TransCelerate Biopharma is focused on advancing innovation in R&D, identifying and solving common R&D challenges and further improving patient safety, with the goal of delivering more high quality medicines to patients. In 2013, they announced its Clinical Trial Comparator Network initiative to show a mutual commitment to offer secure and rapid supply of comparator drug products. The aim of this article is to unpack the section on 'Comparator Drugs' and analyse the rationale for attempting to achieve their objectives.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement